BiomX (NYSEAMERICAN:PHGE) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of BiomX (NYSEAMERICAN:PHGE) in a research note published on Wednesday,Benzinga reports. They currently have a $2.00 price target on the stock.

BiomX Stock Performance

Shares of PHGE opened at $0.74 on Wednesday. The stock has a market capitalization of $13.44 million, a PE ratio of -0.23 and a beta of 1.31. BiomX has a fifty-two week low of $0.48 and a fifty-two week high of $8.55.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).